Category: General

How Matinas Biopharma Scores On My 5 C’s

Shares of Matinas Biopharma Holdings Inc. (MTNB) have performed extremely well over the past few months, up a whopping 365% since September 1, 2016. That kind of impressive move is representative of why investors are attracted to small-cap biopharma stocks. The right call can make you a lot of money in just a short period…

Narcotic Bowel Syndrome An Intriguing Opportunity For Vitality Biopharma

Vitality Biopharma, Inc. (VBIO) is developing a new class of cannabinoid prodrugs, known as cannabosides, to overcome the limitations of raw Cannabis sativa or synthetic cannabinoids. It is a strategy I believe can create significant value due to the differentiation of cannaboside products from existing cannabinoids available through prescription or over-the-counter means. The strategy also effectively distinguishes Vitality…

Time To Go Long Brainstorm Cell Therapeutics?

BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is biopharmaceutical company developing adult stem cell-based therapies for a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease (PD). The company’s NurOwn® technology is based on the use of mesenchymal stem cells (MSCs), engineered ex vivo, to express increased amount of neurotrophic factors (NTFs)….

JPM Meeting Notes – VistaGen Therapeutics (VTGN)

I think VistaGen Therapeutics’ (VTGN) AV-101 is one of the more interesting small-cap biopharma assets in mid-stage development. I’ve written in the past that I think AV-101 has blockbuster sales potential. Heck, there was just a Reuters story out today talking about how large and open this market is. The drug is currently in a Phase 2a…

JPM Meeting Notes – MabVax Therapeutics (MBVX)

MabVax Therapeutics (MBVX) is another company I had a very opportunistic meeting with because they announced that morning the IND for MVT-1075 had been filed. If all goes smoothly, we should see MVT-1075 in the clinic in the second quarter 2017. Now we all know billions (if not trillions) of mice have been cured of cancer over…

JPM Meeting Notes – RedHill Biopharma (RDHL)

As expected, much of my meeting with RedHill Biopharma (RDHL) was focused on the company’s newly acquired rights to Donnatal® in certain areas of the U.S. Now I’ve been traveling for the past several days, so I have not had an opportunity yet to do a deep dive into Donnatal but what I do know is that…

JPM Meeting Notes – Matinas Biopharma (MTNB)

In my pervious commentary on Matinas Biopharma (MTNB) called the company one of my best ideas for 2017. That certainly did not change after my meeting with management. My conversations with the company focused on the ongoing warrant exchange and timelines for some of the very important ongoing clinical studies. To review, there are currently two Phase…

JPM Meeting Notes – BriaCell Therapeutics (BCT.V)

BriaCell Therapeutics (BCT.V) anticipates getting the 24-patient Phase 2a study up and enrolling patients by the end of the quarter. That’s good news because even though it’s a small and early-stage program, it’s a big potential value driver on both the market and business development side. BriaCell is moving aggressively toward combination therapy with BriaVax™…

JPM Meeting Notes – Actinium Pharmaceuticals (ATNM)

During my meeting with Actinium Pharmaceuticals (ATNM) we delved deeper into the topic I covered via a separate article last week – the clinical hold placed on Seattle Genetics SGN-CD33A. I can go into a lot more detail if necessary, but I think if investors read that article above they will get the picture. I do not…

What Does SGEN’s Clinical Hold On CD33A Mean For Actinium?

Last week, Seattle Genetics (SGEN) announced that it had received notice from the U.S. FDA that a clinical hold or partial clinical hold has been placed on several early stage trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML). The clinical holds were initiated to evaluate the potential risk of hepatotoxicity in patients who…